



18 December 2014

ACTINOGEN BOARD CHANGES

SYDNEY, 18 December 2014: The Board of Actinogen Limited (Actinogen Medical, ASX:ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer's disease and other major age-related neurodegenerative disorders, is pleased to announce the appointment of Dr Bill Ketelbey as a Managing Director of the Company.

In other Board changes, current Non-Executive Director, Dr Brendan de Kauwe, will retire from the Board effective immediately. The Company would like to thank Dr de Kauwe for his support and efforts during his tenure as a Board member of Actinogen Medical.

ENDS

Actinogen Medical

Martin Rogers

Chairman

P: +61 2 9251 5620

E: martin.rogers@actinogen.com.au

 [@martinfrogers](https://twitter.com/martinfrogers)

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer's and dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and neurological plaques. The company is currently undertaking a second Phase I multiple ascending dose trial in humans with results in mid-2015 and plans to undertake a Phase II study in late 2015.